Mycoses
Drug research and approvals for mycoses: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 696 studies of mycoses are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 696
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 3
Recruiting now
Newest start dates first, of 696 recruiting on ClinicalTrials.gov ↗- Modeling Host-Pathogen Interaction Using Lymphoid OrganoidsNCT06479837 · Not reported · National Institute of Allergy and Infectious Diseases (NIAID) · starts Nov 22, 2026
- Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related DisordersNCT07683104 · Not reported · National Institute of Allergy and Infectious Diseases (NIAID) · starts Nov 10, 2026
- Oral Switch in Bloodstream Infections in Immunocompromised ChildrenNCT07923266 · Phase 4 · Copenhagen University Hospital, Rigshospitalet · starts Nov 9, 2026
- China Aortic Infection and Graft Infection Study: An Ambispective CohortNCT07847346 · Not reported · Shanghai Zhongshan Hospital · starts Nov 1, 2026
- Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living…NCT07830329 · Phase 2 · Regeneron Pharmaceuticals · starts Oct 29, 2026
- A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HSNCT07855276 · Phase 1 · Novartis Pharmaceuticals · starts Oct 29, 2026
- Factors Associated With Positive Post-Treatment STI Tests and Sexual Knowledge, Attitudes, Behaviors and PracticesNCT07936214 · Not applicable · Centre Hospitalier de Martigues · starts Oct 29, 2026
- A Safety Trial to Evaluate an Orally Ingested Yeast Modified to Express a Tetra-specific Anti-toxin for Clostridioides…NCT07649096 · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID) · starts Oct 29, 2026
- Study of BK1803 in Healthy InfantsNCT07793513 · Phase 3 · Tanabe Pharma Corporation · starts Oct 21, 2026
- Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Ductal AdenocarcinomaNCT07828236 · Phase 1 · Loki Therapeutics, Inc. · starts Oct 15, 2026
Drug pipeline
8 approved, 8 in phase 3, 5 in phase 2, 9 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Posaconazole, Voriconazole, Itraconazole, Amphotericin b, Caspofungin, Clotrimazole, Triamcinolone acetonide, Miconazole
- Micafungin
- Phase 3 1,3-beta-glucan synthase inhibitor
- Fluconazole
- Phase 3 Cytochrome P450 51 inhibitor
- Isavuconazole
- Phase 3
- Metronidazole
- Phase 3 DNA inhibitor
- Rifabutin
- Phase 3 Bacterial DNA-directed RNA polymerase inhibitor
- Azithromycin
- Phase 3 Bacterial 70S ribosome inhibitor
- Isavuconazonium
- Phase 3 Lanosterol 14-alpha demethylase inhibitor
- Polihexanide
- Phase 3 Cell membrane disrupting agent
- Fosmanogepix
- Phase 2 GPI-anchored wall transfer protein 1 inhibitor
- Olorofim
- Phase 2 Dihydroorotate dehydrogenase (quinone), mitochondrial inhibitor
- Natamycin
- Phase 2 Ergosterol sequestering agent
- Pezadeftide
- Phase 2
- Rolusafine
- Phase 2
- Ibrexafungerp
- Phase 1 1,3-beta-glucan synthase inhibitor
- Rifampin
- Phase 1 Bacterial DNA-directed RNA polymerase inhibitor
- Anidulafungin
- Phase 1 1,3-beta-glucan synthase inhibitor
- Terbinafine
- Phase 1 Squalene monooxygenase inhibitor
- Ravuconazole
- Phase 1 Cytochrome P450 51 inhibitor
- Rezafungin
- Phase 1 Candida inhibitor
- Dextrose
- Phase 1
- Manogepix
- Phase 1
- Oteseconazole
- Phase 1 Lanosterol 14-alpha demethylase inhibitor
How its trials ended
588 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 147 whose ending is known, 40% met their primary endpoint, 3% missed it and 56% stopped early.
- Completed, result not reported27947%
- Ongoing9616%
- Status unknown6611%
- Met its primary endpoint5910%
- Stopped: other or unclear376%
- Stopped: enrollment or feasibility254%
- Stopped: sponsor or business decision122%
- Missed its primary endpoint51%
- Stopped: funding51%
- Stopped: lack of efficacy41%
Medicines authorised in the EU
Newest first| Jul 25, 2019 | Posaconazole AccordPosaconazole · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Jul 25, 2019 | Posaconazole AHCLPosaconazole · generic | Accord Healthcare S.L.U. | EMA ↗ |
| May 27, 2015 | Voriconazole Hikma (previously Voriconazole Hospira)Voriconazole · generic | Hikma Farmaceutica (Portugal) S.A. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA